ID   YDOV-151
AC   CVCL_A1KC
SY   YongDong OVarian-151
DR   ABM; T8070
DR   GEO; GSM4013288
DR   Wikidata; Q102115145
RX   PubMed=19188485;
RX   PubMed=19478469;
RX   PubMed=20596667;
RX   PubMed=31615043;
CC   Population: Korean.
CC   Doubling time: 19 hours (PubMed=19478469).
CC   HLA typing: A*38,38; B*58,58; C*03,03; DRB1*03,04 (PubMed=19478469).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=20596667
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D3S1358: 15,16
ST   D5S818: 12
ST   D7S820: 11,12
ST   FGA: 25
ST   TH01: 8,9
ST   TPOX: 6
ST   vWA: 17
DI   NCIt; C4026; Ovarian mucinous cystadenocarcinoma
DI   ORDO; Orphanet_398961; Mucinous adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   20Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 10-04-25; Version: 5
//
RX   PubMed=19188485; DOI=10.1369/jhc.2009.953257; PMCID=PMC2675069;
RA   Cho H., Kim J.-H.;
RT   "Lipocalin2 expressions correlate significantly with tumor
RT   differentiation in epithelial ovarian cancer.";
RL   J. Histochem. Cytochem. 57:513-521(2009).
//
RX   PubMed=19478469; DOI=10.1620/tjem.218.129;
RA   Cho H., Lim B.J., Kang E.S., Choi J.S., Kim J.-H.;
RT   "Molecular characterization of a new ovarian cancer cell line,
RT   YDOV-151, established from mucinous cystadenocarcinoma.";
RL   Tohoku J. Exp. Med. 218:129-139(2009).
//
RX   PubMed=20596667; DOI=10.3892/ijo_00000688;
RA   Chay D.B., Cho H., Lim B.J., Kang E.S., Oh Y.J., Choi S.M., Kim B.W.,
RA   Kim Y.T., Kim J.-H.;
RT   "ER-60 (PDIA3) is highly expressed in a newly established serous
RT   ovarian cancer cell line, YDOV-139.";
RL   Int. J. Oncol. 37:399-412(2010).
//
RX   PubMed=31615043; DOI=10.3390/cancers11101553; PMCID=PMC6826427;
RA   Choi J.-A., Kwon H., Cho H., Chung J.-Y., Hewitt S.M., Kim J.-H.;
RT   "ALDH1A2 is a candidate tumor suppressor gene in ovarian cancer.";
RL   Cancers (Basel) 11:1553.1-1553.18(2019).
//